News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Columbia Laboratories, Inc. (CBRX) Comments On FDA Decision On Adeza Biomedical (ADZA)'s Gestiva


10/23/2006 10:32:01 AM

LIVINGSTON, N.J.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (“FDA”) has issued an approvable letter to Adeza Biomedical for their synthetic progestogen, 17-alpha-hydroxyprogesterone caproate (trademarked “Gestiva”), Adeza’s candidate for prevention of recurrent preterm birth. Final FDA action is subject to the completion of an additional animal study and certain other conditions.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES